Brain Tumor Implant Cuts Recurrence by 93% in Major Trial

Brain cancer patients are getting a fighting chance they've never had before, thanks to a postage stamp-sized implant that's rewriting survival odds.

GT Medical Technologies just raised $100 million after its GammaTile device proved superior to standard treatment in a groundbreaking clinical trial. The results, announced at a major cancer conference last month, showed the implant reduced tumor recurrence by 93% and cut death risk by 41% one year after treatment.

Here's what makes this different. When surgeons remove a brain tumor, they leave behind a cavity where rogue cancer cells hide and regroup. Standard radiation treatment can't start until weeks later, after surgical wounds heal, giving those cells precious time to multiply.

GammaTile changes that equation completely. Doctors place the tiny bioresorbable tiles directly in the brain cavity during the original surgery, delivering targeted radiation right where it's needed most. The treatment starts immediately, attacking cancer cells when they're at their weakest and fewest.

The technology received FDA clearance in 2018 for recurrent tumors and expanded to newly diagnosed cases in 2020. Since then, adoption has grown steadily across the country, with more than 150 leading U.S. cancer centers now offering the treatment to patients.

The recent trial compared GammaTile against the current gold standard: surgery followed by stereotactic radiation therapy. Both approaches proved equally safe, but GammaTile's prevention of tumor regrowth was dramatically better. Patients in the study had newly diagnosed operable brain metastases, meaning cancer that had spread to their brains from elsewhere in their bodies.

The Ripple Effect

This breakthrough reaches far beyond the operating room. Brain metastases affect hundreds of thousands of Americans each year, often striking people already fighting cancer elsewhere in their bodies. For these patients and their families, preventing tumor recurrence can mean more time together, fewer treatments, and genuine hope for the future.

The $100 million investment, led by new investor Viking Global, will accelerate the company's ability to bring GammaTile to community hospitals and cancer centers nationwide. CEO Per Langoe says the funding validates what researchers have believed for years: this technology has the potential to become standard care for operable brain tumors.

GT Medical is also studying the implant in people with newly diagnosed glioblastomas, one of the most aggressive and difficult-to-treat brain cancers. Those results could open the door for even more patients who desperately need better options.

The company has now raised over $214 million since 2020, showing sustained confidence in technology that's delivering real results for real patients.

Sometimes the most powerful innovations are the simplest: putting the right treatment in the right place at exactly the right time.